Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Oral Semaglutide, Gilead JAK Inhibitor, Takeda’s PARP Med OK’ed for Listing on Nov. 18
November 11, 2020
-
BUSINESS Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals
November 11, 2020
-
BUSINESS Incyte Gearing Up for Solo Marketing in Japan, Set to Double Workforce to 70 Staffers
November 10, 2020
-
REGULATORY Japan to Set New Technical Fee for CureApp’s Quit Smoking App
November 10, 2020
-
BUSINESS Big 4 Wholesalers Suffer 80% Drop in Operating Profit on COVID, Discount, Price Battle: 1H 2020
November 9, 2020
-
ORGANIZATION JPMA Sorts Out Challenges for Remote Clinical Trial to Promote Its Introduction in Japan
November 9, 2020
-
BUSINESS Expert Panel Delivers Harsh Verdict on Aducanumab, FDA Decision Due by March 7
November 9, 2020
-
BUSINESS 1st Half Sales of 7 Major Japan Drug Makers Skid 1.9% on Price Cuts, COVID-19; Core Products Brisk
November 6, 2020
-
BUSINESS In a Digital Push, Takeda Encouraging Sales Reps to Gain IT Qualification: Japan Chief
November 5, 2020
-
REGULATORY Ryukaikon Confab Finally Set for November 24; Can Japan Improve Drug Distribution Environment Again?
November 4, 2020
-
BUSINESS Ex-Merck Serono President Leo Lee Becomes Japan Chief of Novartis
November 2, 2020
-
BUSINESS Emerging from Repeated Price Cuts, Opdivo’s Japan Sales Could Top 100 Billion Yen in FY2020
October 30, 2020
-
REGULATORY Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
-
BUSINESS GSK Might Adjust Shipments for Cervarix as Surge in Demand Expected
October 29, 2020
-
BUSINESS Copay Rose for Some Patients as Leuplin Issue Triggered Shortage of 6-Month Depot: HCPs
October 28, 2020
-
BUSINESS Pharma’s Half-Year Earnings Season in Full Swing from This Week
October 27, 2020
-
BUSINESS Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
-
REGULATORY PM Suga Vows to Work towards Annual Price Revisions: Diet Policy Speech
October 27, 2020
-
REGULATORY 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
-
BUSINESS Novartis Looks to Solidify Presence in Multiple Sclerosis Arena with Mayzent, then Ofatumumab
October 23, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…